Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of OPIOID RECEPTOR was performed using 70% confluent log phase Neuro-2A cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with OPRM1 Rabbit Polyclonal Antibody (44-308G) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membranous localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse, Rabbit, Rat|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized peptide derived from an internal region of the human m-opioid receptor.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 2 publications below|
The OPRM1 gene encodes the mu opioid receptor, which is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone. It is also the primary receptor for endogenous opioid peptides beta-endorphin (see POMC, MIM 176830) and the enkephalins (see PENK, MIM 131330). The OPRM1 receptor is a membrane of the G protein-coupled receptor family (Bond et al., 1998 [PubMed 9689128]). There are at least 3 types of opioid receptors, mu, kappa (OPRK1; MIM 165196), and delta (OPRD1; MIM 165195), each with a distinct pharmacologic profile (Chen et al., 1993 [PubMed 8393525]).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Familial hemiplegic migraine type 1 mutations W1684R and V1696I alter G protein-mediated regulation of Ca(V)2.1 voltage-gated calcium channels.
44-308G was used in western blot to assess the effects of G protein-dependent modulation on mutations W684R and V696I which cause familial hemiplegic migraine type.
|Garza-López E,Sandoval A,González-Ramírez R,Gandini MA,Van den Maagdenberg A,De Waard M,Felix R||Biochimica et biophysica acta (1822:1238)||2012|
Quantitative Detection of µ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice.
44-308G was used in western blot to assess different antibodies used to detect MOP.
|Kasai S,Yamamoto H,Kamegaya E,Uhl GR,Sora I,Watanabe M,Ikeda K||Current neuropharmacology (9:219)||2011|
HMOP; KIAA0403; LMOR; M-OR-1; MOP; MOP receptor; MOR; MOR-1; MOR-1C; MOR1; mu 1; Mu opiate receptor; Mu opioid receptor; Mu opioid receptor hMOR-1a; mu opioid receptor splice variant mMOR-1Z; mu opioid receptor splice variant rMOR-1S; mu opioid receptor splice variant rMOR-1Z; Mu-type opioid receptor; MUOR1; Opioid mu receptor; Opioid mu-type receptor; Opioid receptor; Opioid receptor B; opioid receptor, mu 1; OPRM; OPRM1
LMOR; M-OR-1; MOP; MOP-R; MOR; MOR-1; MOR-1O; MOR1; MORA; muOR; OPRM; OPRM1; Oprrm1; Ror-b